Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up

Table 1

Study withdrawal and reason for withdrawal.

	Randomization population${}^1$		On-treatment population${}^2$		Total
	MMF group${}^3$ $(n=48)$	Control group${}^4$ $(n=22)$	Group I${}^5$ $(n=56)$	Group II${}^6$  $(n=14)$	$(n=70)$
Study withdrawal	5 (10.4%)	3 (13.6%)	7 (12.5%)	1 (7.1%)	8 (11.4%)
Graft loss	2 (4.2%)	2 (9.1%)	3 (5.4%)	1 (7.1%)	4 (5.7%)
$P$-value^7	.585		1.000
Death	0 (0%)	1 (4.5%)	1 (4.5%)	0 (0%)	1 (1.4%)
Other${}^8$	3 (6.3%)	0 (0%)	3 (5.4%)	0 (0%)	3 (4.3%)

${}^1$ Patients randomized to receive either MMF or CsA treatment in the initial study phase.
${}^2$ Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
${}^3$ Patients who received 2 g MMF per day and 50% of the initial CsA dose.
${}^4$ Patients who received the usual CsA dose.
${}^5$ Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
${}^6$ Patients without a mycophenolic acid derivative at the end of the follow up phase.
${}^7$ 1 patient moved, 2 patients did not perform visit at month 60.
${}^8$ Comparison between groups of patients who had graft loss.